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ABSTRACT 
Background and aims: Barrett’s esophagus (BE) is a common premalignant lesion for 
which endoscopic surveillance is recommended.  This strategy is limited by considerable 
variations in clinical practice.  We conducted an international, multidisciplinary, systematic 
search and evidence-based review of management strategies for BE and provided consensus 
recommendations for the management of patients with non-dysplastic, indefinite and low 
grade dysplasia (LGD). 
Methods:  We defined the scope and then proposed statements, searched electronic 
data-bases yielding 20,558 publications which were screened online and developed into the 
evidence-base.  We used a Delphi consensus process, with an 80% agreement threshold, 
using GRADE to categorize the quality of evidence and strength of recommendations. 
Results: in total, 80% of respondents agreed with 55 of 127 statements in the final 
voting rounds and 15 of the 25 post hoc statements. 
Population endoscopic screening is not recommended except for very high risk cases 
of over 60’s males with chronic uncontrolled reflux.  A new international definition of BE 
was agreed.  For any degree of dysplasia, at least two specialist GI pathologists are required.  
Risk factors for cancer include males, length of BE and , obesity.  Endoscopic resection 
should be used for visible, nodular areas.  Surveillance is not recommended if there is less 
than 5 years life expectancy.  Management strategies for indefinite dysplasia (IND) and LGD 
were identified, including a de-escalation strategy of surveillance for lower risk patients and 
escalation to intervention with follow up for high risk patients. 
Conclusions: In one of the largest evidence based consensus processes in 
gastroenterology we made key clinical recommendations for the escalation/de-escalation of 
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BE in clinical practice.  We made strong recommendations for the prioritization of future 
research.   
 
[Abstract word count 264] 
 
Keywords: BOB CAT; Esophageal Cancer; Treatment Strategy; Systematic Analysis 
 
BACKGROUND 
BE is a premalignant condition of metaplastic columnar epithelium of any histological 
subtype (Fitzgerald et al., 2014) that replaces the stratified squamous epithelium.  BE is 
more common in developed countries, affecting 2% of the general adult population 
(Ronkainen et al., 2005) particularly in those with heartburn or undergoing an upper 
gastrointestinal endoscopy, (Ford et al., 2005), (Malfertheiner et al., 2005);  furthermore the 
incidence of BE at diagnostic endoscopy has been reported to be rising independently of an 
increase in the number of endoscopies carried out (Coleman et al., 2011) suggesting a true 
increase in incidence rather than a higher detection rate.  BE is strongly associated with 
gastro-esophageal reflux disease (GERD), suggesting that BE related adenocarcinoma 
develops from chronic esophagitis, through benign BE, and dysplasia (Figure 1) although the 
precise relationship is unclear.(Taylor and Rubenstein, 2010), (Ronkainen et al., 2011), 
(Erichsen et al., 2012) , (Malfertheiner et al., 2012) The incidence of EA is increasing in 
developing countries, (Lagergren and Lagergren, 2013) , (National Cancer Institute. Fast 
stats, 2000-2010) and it is estimated that patients with BE have at least a 1 to 5% lifetime  
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risk of developing esophageal adenocarcinoma (EA).  (Hvid-Jensen et al., 2011),  (Desai et al., 
2012),  (Jung et al., 2011), (Bhat et al., 2011)  
The most recent guidelines from the British (Fitzgerald et al., 2014 and American 
societies (Spechler et al., 2011a), (Fitzgerald et al., 2014) recommended surveillance 
endoscopy every 2 to 5 years in patients with BE to detect early stages of the neoplastic 
process and early signs of high-grade dysplasia (HGD) treatable by endotherapy. (Spechler et 
al., 2011a), (Spechler et al., 2011b) Other published consensus papers on the topic have 
impacted on clinical management, but have focused on BE in general, (Spechler et al., 
2011a), (Fitzgerald et al., 2014) HGD (Bennett et al., 2012b) or specific therapies.  (NICE, 
2010) 
Endoscopic and histopathologic classification of BE dysplasia is highly variable among 
and within countries.  This consensus specifically included members from outside the UK 
and USA to obtain an international viewpoint.  Considering the impact of a diagnosis of non-
dysplastic BE on the patient, and the cost and risk of endoscopic surveillance and the 
consequences of progression to invasive EA if management strategies fail, there is a need 
for an international consensus approach to non-dysplastic BE patients and those with LGD.    
Our previously published guideline ‘BAD CAT’ addressed the management of high-grade 
dysplasia and early cancer in BE. The motivation for doing this current review was to show 
how poor the evidence is and highlight areas for research in non-dysplastic BE and low 
grade dysplasia (LGD). We analyzed risk factors, current practice, and therapies, to inform 
clinical practice for a world-wide audience.  In addition BOBCAT was a much larger review, 
using GRADE and extra voting rounds. We consequently established a new international 
definition of BE, and we provide clear escalation and de-escalation strategies for non-
9 
 
dysplastic, indefinite for dysplasia (IND) and LGD. We named this consensus the Benign 
Barrett's and CAncer Taskforce consensus group 'BOB CAT'. 
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METHODS  
The specific population under consideration consisted of adults aged 18 years or 
older with a diagnosis of non-dysplastic BE or LGD; but excluding those with esophagitis 
alone, or invasive or advanced stages of EA. HGD, intramucosal EA (T1m or T 1a) or 
superficial submucosal EA (T1sm1 or T1b), which were reviewed in the previous consensus 
(Bennett et al., 2012b).  
We used an evidence-based Delphi process  (Powell, 2003),  (Sinha et al., 2011) to 
develop consensus statements for non-dysplastic BE and LGD.  The process (Bennett et al., 
2012b) permitted anonymous individual feedback and changes of views during the process, 
together with controlled feedback of evidence regulated by the coordinator (CB) and the 
consensus chair (JJ).  The principal steps in the process were: (1) selection of the consensus 
group; (2) identification of areas of clinical importance (3) systematic literature reviews to 
identify evidence to support each statement; (4) draft statements and discussions 
supported by evidence specific to each statement, by panels; (5) 3 rounds of anonymous 
voting and feedback, plus 3 supplementary rounds of post-hoc voting following peer 
reviewers’ requests. The respondents were asked to choose 1 of the following for each 
statement; agree strongly (A+), agree with reservation (A), undecided (U), disagree (D) or 
disagree strongly (D+) When no strong agreement was reached, we re-phrased the 
statement in a negative fashion to see if this would provoke stronger agreement.  A 
description of any concerns about the statement was provided from the online comments 
of the respondents, allowing statement chairpersons to modify statements and discussion  
prior to the next voting round. 
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Evidence-based discussions with key references were provided; it was the statement on 
which participants voted.     
We defined consensus as 80% of respondents strongly agree or agree with reservation.  If 
>50% of respondents strongly agreed with the statement, it was accepted as a measure of 
agreement (Figure 2).  With each round of the main consensus process, (both the main 
rounds and the post hoc voting rounds) fewer statements received less than 20% 
agreement, reflecting comments on the inclusion of negatively phrased statements (Figure 
2).  (6) GRADE assessments of the strength and quality of the evidence and strength of the 
recommendations. GRADE ratings were not applied when recommendations were 
considered to refer to universally excepted good practice rather than evidence based 
decision on two or more competing management strategies and these statements are 
identified as good practice recommendations. Treatment comparisons were given one of 
four GRADE scores reflecting the quality of the evidence: high-, moderate-, low-, or very 
low-quality evidence, (Guyatt et al., 2011) and we used GRADE to quantify the strength of 
recommendations as strong, or conditional (Guyatt et al., 2008a, Guyatt et al., 2008b)  
Further details are listed in the online Appendix (Methods).  This paper uses a similar 
but larger and improved methodology to that published in 2012. (Bennett et al., 2012b)  
However the topic being covered is distinctly different.  Specifically the previous paper 
covered the management of BE with either HGD  or locally invasive cancer whereas the 
topic being covered here excludes these areas totally and instead covers the management 
of non-dysplastic, indefinite for dysplasia (IND) and LGD in BE.  
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RESULTS  
We reached consensus in the final round, (defined as 80% of the respondents who 
took part in the final voting rounds indicating that they agree strongly or agree with 
reservation), in 55/127 statements.  Agreement among at least 50% of respondents was 
achieved in 90 of 102 statements (Figure 2) with a corresponding decrease in null votes by 
the final round.     
The core group reviewed the results and after the final round, and selected and 
summarized 10 key groups of 30 statements that represent clinically relevant areas in 
screening, diagnosis, surveillance, approaches to treatment, and prevention of progression 
to HGD and early EA in patients with BE.  We made these selections on the basis of clinical 
relevance with a high degree of consensus to guide clinical practice (Figure 3).   
In total 20,558 references (Figure 4 Flow diagram) (Liberati et al., 2009) were 
available for review and inclusion.   
Additional statements are provided in an online appendix (Results) to this 
publication and all the statements were archived: (http://mdpub.org/bobcat/index.php).   
Statement agreement 
Definition of BE 
1. BE is defined by the presence of columnar mucosa in the esophagus and it should be 
stated whether intestinal metaplasia (IM) is present above the gastro-esophageal 
junction. Overall agreement 88%. A+ 49.3%, A 38.7%, U 4%, D 5.3%, D+ 2.7%.   
RECOMMENDATION:  good practice includes the adoption of internationally accepted 
pathology criteria for both benign and dysplastic BE.   
Good practice recommendation. 
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The definition and hence diagnostic criteria for BE remains controversial, varies 
worldwide, and continues to divide opinion. In the USA there is strong endorsement that 
the term 'Barrett's esophagus' should be used only for patients who have intestinal 
metaplasia in the esophagus.  This definition of BE is at odds with current UK and Japanese 
(Takubo et al., 2012), (Rugge et al., 2014) opinion and the definition in updated BSG 
guidelines (Fitzgerald et al., 2014) which do not require IM to establish the diagnosis. 
Recognition of the increased risk of neoplastic progression when IM is present is 
acknowledged, however, in the updated BSG guidelines in that it is proposed that BE 
surveillance is based on risk stratification (including the presence of IM). The presence of 
IM can be limited by sampling error in mucosal biopsies but can virtually always be 
identified in endoscopically-visible columnar metaplasia provided a sufficient number of 
biopsies are taken over a sufficient time scale (Harrison et al., 2007). Although other data 
show that a cohort of between 9- 25% of patients have never had goblet cells detected, 
other authors question the need for IM for the diagnosis of BE (Riddell and Odze, 2009). 
Defining IM by the morphological identification of mucosal goblet cells has now been 
shown to be problematic as there is evidence that the non-goblet columnar epithelium 
may be intestinalized, showing similar molecular abnormalities as goblet cell epithelium, 
and with similar risk of neoplastic progression (Hahn et al., 2009). There is also growing 
evidence that challenges the notion that EA is always preceded by IM, and suggesting that 
there is no difference in the rate of development of EA between patients with and without 
IM. The difference in definition clearly has the potential to greatly influence the frequency 
of diagnosis of BE at index endoscopy, (Westerhoff et al., 2012) and the number of 
patients entering into follow up and surveillance programs. (Balasubramanian et al., 2012)  
There are three main caveats which should be borne in mind to ensure that this new 
global definition of BE is clinically meaningful that the gastro-esophageal junction is 
irregular, and tongues of 1cm or less may be a natural phenomenon (even if IM is present, 
it can occur in the cardia of the stomach); in greater than 80 to 90% of cases of BE a hiatal 
hernia also co-exists; and that the diagnosis must be an agreed clinico-pathological 
definition, but there are cases where either the pathologist of the endoscopist may be 
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able to overrule the other (examples of this are long segments of BE greater than 3cm, 
most hiatal hernias are 3cm or less, and micro-metaplasia which can be missed 
endoscopically but picked up by the pathologist).  
In conclusion, BE is a combined endoscopic and pathological diagnosis; BE is defined 
by the endoscopic presence of columnar mucosa of the esophagus and the pathology 
report should state whether IM is present or absent in the tissue samples taken from 
above the gastro-esophageal junction.  
2. The optimal definition of LGD in BE includes the use of an agreed internationally-
recognized criteria including increased nuclear/cytoplasmic ratio, hyperchromatic and 
heterochromic nuclei.  Overall agreement 83.60%.  A+ 21.9%, A 61.7%, U 7.8%, D 7.8% 
D+0%  
RECOMMENDATION:  good practice includes the adoption of internationally accepted 
pathology criteria for both benign and dysplastic BE.   
Good practice recommendation. 
 
Unequivocal low grade intraepithelial neoplasia (WHO, 2010) criteria typically 
include preserved nuclear polarity, nuclear heterogeneity and margination, few mitoses, no 
atypical mitoses, decreased numbers of transition to adjacent glandular epithelium.  
Architectural changes are absent or minimal in LGD but may include irregular growth 
patterns, parallel tubules, minimal gland distortions, no single cell budding, no significant 
branching of glands, no solid or cribriform patterns, and normal lamina propria.  There are 
intra-observer variations in the diagnosis and grading of LGD and in differentiating it from 
reactive changes. (Kaye et al., 2009), (Haggitt, 1994) Criteria for grading foveolar and 
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serrated dysplasia have not been fully addressed in the literature.  (Mahajan et al., 2010) , 
(Kushima et al., 2005)   In the future image analysis may help to refine the criteria further.  
(Sabo et al., 2006)    
 
 
Diagnosis 
3. Reporting by a single pathologist is satisfactory for the diagnosis of non-dysplastic BE.  
Overall agreement 80.8%. A+ 30.4%, A 50.4%, U 13.6%, D 4%, D+ 1.6%.   
RECOMMENDATION: we recommend that for benign BE, a single pathologist report 
is satisfactory for management.   
Good practice recommendation. 
 
The evaluation of routine biopsies by a single specialist (in BE) histopathologist for 
the diagnosis of BE is satisfactory. (Hirschowitz et al., 2013)  
 
4. A consensus between at least two specialist gastrointestinal (GI) pathologists is 
required for the diagnosis of LGD. Overall Agreement 90.8%.  A+ 48.7%, A 42.1%, U 
3.9%, D 5.3%, D+ 0%. 
 
The diagnosis of LGD  is potentially a watershed in the natural history of BE as most 
studies have shown that it indicates a much higher chance of progression than non-
dysplastic BE. It therefore generally results in a much more intensive follow-up schedule 
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and as newer less invasive treatment modalities such as radiofrequency ablation (RFA) 
gain acceptance it may soon be the trigger for definitive treatment. For this reason, it is 
vital that pathologists diagnose LGD accurately. Studies which have looked at pathologist 
interobserver agreement for the diagnosis of LGD show at best fair agreement with 
Kappa scores ranging from 0.15-0.4, (Sanders et al., 2012), (Wani et al., 2011b, Kerkhof 
et al., 2007) (increasing to κ=0.61 (0.53-0.69), when probe-based confocal laser 
endomicroscopy (pCLE) was employed (Gaddam et al., 2011) However, as differentiation 
between LGD and HGD is difficult, agreement for the presence of dysplasia vs. no 
dysplasia may be considerably better than this. Nevertheless, several studies have 
shown that when LGD is diagnosed by general pathologists the progression rate is low 
and that when these cases are reviewed by experts many are downgraded to non 
dysplasia (ND). This purified dysplastic cohort then has a relatively high rate of 
progression. (Kaye et al., 2009) , (Curvers et al., 2010) At least two studies have also 
shown that the chance of progression of dysplasia is proportional to the number of 
pathologists who agree a case is dysplastic. (Kaye et al., 2009), (Skacel et al., 2000) In  
the recent Amsterdam paper (Duits et al., 2014) and the SURF study, (Phoa et al., 2014) 
only about a quarter of LGD were confirmed after specialist review by a panel  and there 
was a clear difference in progression rates. For these reasons, it is recommended that 
the initial diagnosis of dysplasia is agreed by at least 2 GI pathologists who are at least 
partially specialized in gastrointestinal pathology and who are experienced in the 
pathology of BE. The new BSG guidelines (Fitzgerald et al., 2014) actually go slightly 
further and recommend that 'Given the important management implications for a 
diagnosis of dysplasia, we recommend that all cases of suspected dysplasia are reviewed 
by a second GI pathologist, with review in a cancer center if intervention is being 
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considered'. For follow up biopsies in patients who already have an established 
consensus diagnosis of dysplasia at the same institution, it could be argued that this 
requirement could be relaxed although there are no data to support this either way. 
5. In BE, the diagnosis of indefinite for dysplasia (IND) can be used for a variety of 
histopathological appearances and requires consensus agreement between at least 2 
GI pathologists. Overall Agreement 80%.  A+ 37.3%, A 42.7%, U 14.7%, D 4%, D+ 1.3%. 
 
The meaning of such a diagnosis in a pathology report can be several fold. Firstly it may 
refer to an epithelium, which possesses the cytological features of dysplasia (nuclear 
pleomorphism, hyperchromasia, loss of polarity), but features are present only in the base 
of the crypts and not in the surface epithelium which may be absent. Lack of surface 
maturation has, by convention been required for the diagnosis of dysplasia, but more 
recently there has been recognition of crypt dysplasia without maturation in up to 7.3% of 
BE cases. (Lomo et al., 2006) Secondly, regenerative changes may mimic dysplasia, whereby 
there is a constellation of cytological atypical features, evidenced by an often marked 
increase in mitotic figures, nuclear pleomorphism and loss of cell polarity, associated with 
inflammation, but a retained architecture, and no sharp cut-off between normal and 
abnormal epithelium. It is clear that reproducibility of diagnosis of IND is poor. (Coco et al., 
2010) , (Montgomery et al., 2001), (Sonwalkar et al., 2010) 
RECOMMENDATION:  we recommend two or more specialist pathologists should be 
involved when any grade of dysplasia is diagnosed. 
Conditional recommendation, low quality evidence 
18 
 
 
6. A proforma (standardized reporting form) should be used to report BE.  Overall 
agreement 83.9%.  A+ 46%, A 37.9%, U 14.5%, D 1.6%, D+ 0% 
RECOMMENDATION: using a proforma for pathology reporting in non-dysplastic BE 
is good practice.  Good practice recommendation.   
The use of a proforma report is strongly recommended in the setting of BE, at least 
for the reporting of biopsies from the index endoscopy  (Zaninotto et al., 2007), (Curvers et 
al., 2008) , (Kaye et al., 2009), (Cross et al., 1998)  to improve completeness, accuracy, and 
reproducibly of recording and reporting the morphological features of BE.  Proposed 
dataset/data items that could be included in a draft proforma may include: the number of 
biopsies per cm (including levels); mucosal subtypes e.g.  squamous, columnar, mosaic, 
presence or absence of reflux esophagitis); IM presence or absence; active or chronic 
inflammation, with grading into mild /moderate /severe; presence of native structures; 
Vienna neoplasia category (1: no dysplasia, 2:IND, 3: LGD, 4:  HGD, 5: invasive EA); p53 
immunostaining. 
Screening to detect BE 
7. Endoscopic screening for BE is not justified in the general population.  Overall 
Agreement 94.2%.  A+ 58.7%, A 35.5%, U 2.5%, D 1%, D+1%. 
RECOMMENDATION: we suggest against screening the general population for BE 
endoscopically or with non-endoscopic methods.   
Conditional recommendation, low quality evidence. 
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Endoscopic screening in the general population is not currently recommended.  Markov 
models that have been created, albeit in 50 year old men with GERD and not the general 
population, have not shown an advantage to screening. (Rubenstein et al., 2007) The 
incidence of EA  resulting from BE is too low (Bhat et al., 2011) to warrant broad population 
based screening.  It follows that non-endoscopic screening methods, given their lower 
sensitivity and/or specificity are not indicated. Transnasal endoscopy has good accuracy, 
(Shariff et al., 2012) but, it needs to be validated outside tertiary centers and population 
screening for BE is still controversial. 
8. Endoscopic screening for BE is recommended, to decrease the risk of death from 
esophageal adenocarcinoma, in men over age 60, with GERD symptoms for 10 yrs. 
Overall Agreement 84%.  A+ 16%, A 68%, U 8%, D 6.7%, D+ 1.3%. 
 
The risk of EA  is strongly associated with male sex; this cancer is uncommon among 
women. This may be due to a lower frequency of BE among women, to a lower risk of BE 
progressing to  EA, or both (Pohl et al., 2013). One of the largest population-based cohorts 
to date, including 8522 patients with BE, found that men with BE had almost a two-fold 
increased risk of developing esophageal adenocarcinoma, compared with women.  (Bhat et 
al., 2011) Similar results, of an increased risk for men to progress to dysplasia or cancer, 
have been reported from other studies.  (Badreddine et al., 2010) A meta-analysis which 
pooled results from 47 reports of cancer incidence in BE also noted that men with BE were 
approximately twice as likely as women to progress to EA. (Yousef et al., 2008) Furthermore, 
work from Rubenstein et al found that the risk of EA in men less than age 50 was very low, 
beginning to increase after age 50 and become substantial for men after age 60 with weekly 
GERD symptoms. (Rubenstein et al., 2011) Also, GERD symptoms for 10 years are strongly 
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predictive of development of EA. (Lagergren et al., 1999) In conclusion even if the symptoms 
are well controlled, the length of time with GERD in this age group makes BE a clinically 
meaningful lesion to identify. This would suggest that men with this clinical profile should be 
screened. (Spechler, 2013) 
RECOMMENDATION: we suggest endoscopic screening to detect BE (and for the 
investigation of dyspepsia) in men over age 60  with prolonged GERD (10 year or more) 
symptoms. 
Conditional recommendation, very low quality evidence. 
 
  Risk factors 
There are accepted risk factors in BE for progression to EA. 
9. The risk of progression of BE metaplasia to HGD or EA is related to central obesity 
(measured by waist circumference, waist hip ratio or visceral abdominal fat area).  
Overall agreement 86.6%.  A+ 18.5%, A 68.1%, U 10.1%, D 3.4%, D+ 0% 
Cross-sectional studies have shown some association between measures of 
abdominal fat and biomarkers of progression.  (Vaughan et al., 2002) Waist–hip ratio of BE 
patients has been shown to correlate with the prevalence of combined LGD and HGD.  (Moe 
et al., 2000) , (Hardikar et al., 2013) Furthermore, serum levels of leptin and insulin 
resistance were strongly correlated with increased risk of progression to EA in BE subjects 
followed prospectively. (Duggan et al., 2013)  A recent meta-analysis showed a consistent 
association (BMI and reflux independent) between parameters linked to central obesity and 
esophageal inflammation, metaplasia and EA.  (Singh et al., 2013)  
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10. The risk of non-dysplastic BE progressing to dysplasia or EA is greater among men than 
among women.  Overall agreement 94.4%.  A+ 49.2%, A 45.2%, U 4.8%, D 0.8%, D+ 0%. 
One of the largest population-based cohorts to date, including 8522 patients with 
BE, found that men with BE had almost a two-fold increased risk of developing EA, 
compared with women.   (Bhat et al., 2011)  Similar results have been reported from other 
studies.  (Anandasabapathy et al., 2007)  A meta-analysis which pooled results from 47 
reports of cancer incidence in BE noted that men with BE were approximately twice as likely 
as women to progress to cancer.  (Yousef et al., 2008) 
11. The risk of progression of BE metaplasia is related to (longer) length of BE.  Overall 
agreement 96%.  A+ 57.3%, A 38.7%, U 4%, D 0%, D+ 0% 
In a 15-year prospective study of endoscopic surveillance  (Iftikhar et al., 1992)  
columnar-lined esophagus was significantly longer (8 cm or more) in those who developed 
dysplasia as compared with the whole group, while no patient with a columnar-lined 
esophagus of <8 cm was found to develop dysplasia or EA.  Doubling of the length of BE, 
increased the risk of development of EA by  a factor of 1.7 (Menke-Pluymers et al., 1993) 
The prevalence of dysplasia in long segment BE (LSBE) was 2 times greater than in short 
segment BE (SSBE).  (Hirota et al., 1999)  The results of a multicenter cohort study (Sikkema 
et al., 2011) multivariable analysis showed that amongst other factors length of BE (RR 1.11 
per cm increase in length; 95% CI 1.01-1.2), was a significant predictor of progression to 
HGD or EA. 
 
Endoscopic methods in confirmed BE. 
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12. Endoscopic reporting should be done using a minimum dataset including a record of 
the length using the Prague criteria, presence and size of a hiatal hernia (HH) below 
and esophagitis above the BE segment.  Overall agreement 82.9%.  A+ 50%, A 42.5%, U 
4.2%, D 2.5%, D+ 0.8%.   
An objective scoring system for measuring the length of BE and associated esophagitis 
needs to be used to avoid intra-observer and inter-observer errors in follow up.  The 
Prague criteria, formulated in 2006, (Sharma et al., 2006) provide a uniform set of 
criteria for describing BE and has excellent reliability coefficients among expert 
endoscopists, trainees, (Vahabzadeh et al., 2012) community- based practitioners 
(Alvarez Herrero et al., 2013) across continents (Lee et al., 2010) , (Chang et al., 2009)  
and for the scoring of maximal circumferential and linear extent of BE (Jones et al., 
2002) which may be associated with increased risk of BE and progression to EA 
(Balasubramanian et al., 2012). In addition it is vital to identify the size of the HH below 
in order to avoid false classification of the BE where no BE or a much smaller BE segment 
exists in reality. (Sharma et al., 2006, Sharma et al., 2004)It is recommended that good 
endoscopic practice is advocated, maintained and taught as these standards lead to 
clinically meaningful outcomes (Harrison et al., 2007), (Das et al., 2008), (Bennett et al., 
2012b).  
13. Surveillance and biopsy of BE should be performed by experienced endoscopists, with 
the availability of and training in appropriate techniques and tools, used according to 
standard protocols and with sufficient time allowed for careful inspection.  Overall 
agreement 93.4%.  A+ 55.3 %, A 38.2%, U 3.9%, D 2.6%, D+ 0% 
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RECOMMENDATION: strong research recommendations.   
Further studies are needed on the optimal pathways of management in BE using 
risk factors and biomarkers, to test systematic protocols for biopsy collection in particular 
the optimum number , and the optimal setting for BE surveillance (dedicated lists, 
specialist centers). 
 
In practice, clinicians who initially assess BE patients may have limited experience in 
the management of BE or may have either a medical or surgical training.  In patients 
diagnosed with esophago-gastric cancer, 8-10% have had endoscopies in the 3 years 
preceding diagnosis; these studies include both squamous and adenocarcinoma. (Yalamarthi 
et al., 2004), (Chadwick et al., 2014) For early (stage 0/1) esophago-gastric cancer, 34% had 
not been recognized in the preceding endoscopies, particularly those located in the upper 
esophagus (Chadwick et al., 2014). Among patients in whom no abnormality had been noted 
(definitely missed cancers: 7.2%), endoscopist error was determined to have been the 
failure in 73% (Yalamarthi et al., 2004). A recent study has shown that among patients with 
BE examined by 11 endoscopists at 5 tertiary referral centers, those endoscopists with 
average BE inspection times longer than 1 minute per centimeter of BE detected more 
patients with endoscopically suspicious lesions (54.2% vs 13.3%), and there was a trend 
toward a higher detection rate of neoplasia (40.2% vs 6.7%). Indeed, there was a direct 
correlation between the endoscopists’ mean inspection time per centimeter of BE and the 
detection of patients with neoplasia. (Gupta et al., 2011) This is in line with the well known 
finding that adenoma detection rate among colonoscopists (a key performance indicator) is 
related to colonoscope withdrawal time, with withdrawal times in excess of 6 minutes 
showing higher rates of detection. (Barclay et al., 2006) In another recent study of 69 
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patients referred to a specialist unit with dysplastic BE, only 29 had a visible mucosal 
abnormality found by the referring endoscopist compared to 65 at the specialist unit. 
(Cameron et al., 2014) It was noted that only 57% of the referring endoscopists had used 
high definition endoscopy (which is now recommended for BE surveillance) (Fitzgerald et al., 
2014) and 14% narrow band imaging. While this was interpreted as indicating that all 
dysplastic BE should be examined in referral centers, it is not clear whether examination 
time could have had an influence in the difference in findings. Indeed, BE early neoplasia 
often presents as subtle flat Paris Type II-b lesions (Pech et al., 2007) which can be easily 
missed if inspection is not careful. The ‘Seattle’ protocol (Levine et al., 2000) involves visual 
inspection and multiple biopsies from lesions and at 1- to 2-cm intervals throughout the BE 
segment.  This protocol is safe and leads to an increase in the detection of early neoplasia. 
(Fitzgerald et al., 2001), (Abela et al., 2008) However, non-adherence to BE biopsy guidelines 
is associated with significantly decreased dysplasia detection. (Abrams et al., 2009), (Peters 
et al., 2008b, Das et al., 2008), (Ramus et al., 2008), (Curvers et al., 2008) Although a 4 
quadrant 2 cm Seattle protocol for systematic biopsy is accepted as a standard for BE 
surveillance, (Fitzgerald et al., 2014) it is often not adhered to in practice (Peters et al., 
2008b) which may lead to reduced diagnosis of neoplasia.  (Abela et al., 2008) 
 
14. High resolution endoscopy with targeted biopsies in experienced hands is an effective 
tool for the diagnosis of BE neoplasia.  Overall agreement 89.2%.  A+ 24.2%, A 65%, U 
8.3%, D 2.5%, D+ 0%. 
RECOMMENDATION:  we suggest use of high resolution endoscopy with targeted 
biopsies in expert centers only.  
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Conditional recommendation, low quality evidence. 
Endoscopic surveillance of BE should be performed using high resolution white light 
endoscopy.  (Spechler et al., 2011a) High resolution endoscopes (HRE) that have a resolution 
of 1,000,000 pixels have greatly improved the ability to visualize subtle mucosal 
abnormalities in BE and appear to have higher sensitivity for detecting progression to early 
neoplastic lesions in BE (Wolfsen et al., 2008).  HRE is recommended but requires training 
and experience in its use (particularly in lesion recognition) in all settings, which is most 
likely to be achieved in expert centers. Ideally only those with training and experience in the 
use of HRE should undertake HRE-visualized biopsies . 
 
Surveillance and surveillance intervals 
 
For the purposes of reducing mortality from EA in non-dysplastic BE patients, routine 
surveillance (versus no surveillance) was not supported in this consensus: 
 
15. Among patients with non-dysplastic BE, endoscopic surveillance according to 
recommended guidelines decreases mortality from EA (compared to no surveillance).  
Overall agreement 38.5%.  A+ 13.1%, A 25.4%, U 33.6%, D 21.3%, D+ 6.6%.   
Multiple observational studies have demonstrated that endoscopic surveillance can 
result in earlier detection of EA; however, it is unclear whether surveillance at such intervals 
results in an overall survival benefit in the population.  BE-associated EAs detected through 
surveillance endoscopies were associated with low-stage disease and improved survival 
compared with non-surveillance detected cancers. (Corley et al., 2002),  (Aldulaimi et al., 
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2005) , (Wong et al., 2010)   In contrast, most EAs found in a non-surveillance cohort were 
invasive (more than T1) at index endoscopy. (Wong et al., 2010), (Grant et al., 2013) 
In terms of survival benefit, even though surveillance enables detection of EA at an 
earlier stage, it does not significantly influence overall survival. (Sontag, 2001) , (Corley et 
al., 2013), (Macdonald et al., 2000)   One of the largest retrospective studies (Solaymani-
Dodaran et al., 2013) reported an annual mortality rate from EA of only 0.14%.  A meta-
analysis of 51 studies which included 14,109 patients (Sikkema et al., 2010) found an annual 
rate  of mortality of 0.3% due to EA.  In a population-based cohort study,  (Anderson et al., 
2003) the overall mortality rate in patients with BE was similar to that of an age and sex 
matched control population.  EA accounted for only a small proportion of deaths in these 
patients, most deaths being due to other causes.  From these data and similar results of 
many other studies not cited, EA is an uncommon cause of death in patients with BE, and 
the mortality rate due to EA is low, whether or not patients undergo endoscopic 
surveillance.   
In the absence of agreement on surveillance versus no surveillance for reduction of 
mortality from EA, we did not achieve consensus on statements examining intervals for 
surveillance.  
16. Surveillance of non-dysplastic BE, to decrease the risk of death from EA, should be 
targeted at high risk groups (defined using composite risk factors including, but not 
limited to: age 50 years or older, white race, male sex, obesity and symptoms). Overall 
agreement 96%.  A+ 57.3%, A 38.7%, U 4%, D 0%, D+ 0%.   
 
There are currently no tightly defined and accepted criteria to differentiate those with 
non-dysplastic BE and a higher risk of progression from those at lower risk, and there are no 
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data available yet from RCTs which demonstrate benefits from scheduled surveillance in 
terms of a decrease in mortality due to EA. In the absence of this information, the decision 
to carry out surveillance should be based on risk of progression of BE and should include 
evaluation of factors known to place patients at higher risk of progression. These include, 
but are not limited to: age and sex, length of segment, and symptom duration, frequency 
and severity.  The study by Bhat in 2011,(Bhat et al., 2011) stated that "the risk of cancer 
was statistically significantly elevated in patients with versus without specialized intestinal 
metaplasia (SIM)at index biopsy (0.38% per year vs. 0.07% per year; hazard ratio [HR] = 3.54, 
95% CI = 2.09 to 6.00, P .001)". Analyzing the literature evidence indicates that it is unclear 
that goblet cells precede all EAs in the distal esophagus. (Nunobe et al., 2007) On the other 
hand these data also imply that if goblet cells are present BE has a risk for malignant 
transformation that is considered to be around 0.12 %  per year but due to the low 
frequency this now calls into question the rationale for ongoing surveillance in any patients 
who have BE without dysplasia. (Hvid-Jensen et al., 2011) No conclusive surveillance 
strategies can be drawn up at the moment. 
 
 
RECOMMENDATION: we make no recommendations about surveillance for non-
dysplastic BE, but if undertaken, surveillance should be directed at high risk groups.  
Conditional recommendation, low quality evidence. 
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If surveillance is carried out, the surveillance cycle should stop in patients with less 
than 5 years life expectancy as evidence by the strong disagreement in the following 
statement. 
17. Among patients with non-dysplastic BE who have less than a 5-year life expectancy, 
endoscopic surveillance, compared with no surveillance, decreases mortality from EA.  
Overall agreement 7.6%.  A+3.4%, A 4.2%, U 12.7%, D 35.6%, D+44.1% 
RECOMMENDATION: we suggest against surveillance of non-dysplastic BE in 
patients with a life expectancy of 5 years or less. 
Conditional recommendation, low quality evidence. 
The risk of malignant progression over a 5-year interval, in patients with BE, appears 
low.   (Martinek et al., 2008) , (Bhat et al., 2011) ,(Conio et al., 2003)  When compared with 
patients with other esophageal disorders, and the general population, rates of esophageal 
cancers (both squamous cell carcinomas and EA) and extra-esophageal cancers were similar.  
Estimated 10-year survival rates among the BE, other esophageal disorders and the general 
population were similar.  (Eckardt et al., 2001)  Mortality from EA was only 4.7% in one 
other study.  (Anderson et al., 2003)  Bronchopneumonia and ischemic heart disease are 
more common causes of death in patients with BE than EA and the rate of esophageal 
cancer deaths that might be impacted by BE surveillance is only ~1 in 380 patient years of 
follow-up.  (Moayyedi et al., 2008),  (Solaymani-Dodaran et al., 2005),  (Cook et al., 2007)  In 
a single-center, prospective cohort study in 1239 patients with BE, EA accounted overall for 
less than 3% of all deaths at 5-years.  (Caygill et al., 2012)  Surveillance incurs costs and 
patients under surveillance have a lower quality of life. (Garside et al., 2006)  In patients 
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with multiple co-morbidities or short life expectancy, the risks and benefits should be 
discussed with the patient prior to enlisting for surveillance. 
 
We examined the evidence for the benefits of surveillance in patients with LGD in 
the following two statements:  
18. There are almost no data on different surveillance intervals or its effects among only 
persons with LGD.  Overall agreement 89.3%. A+24%, A 63.9%, U 7.4%, D 3.3%, D+0%.   
 
There was no agreement in our consensus for surveillance intervals in LGD in BE. 
We make no recommendations for practice. 
RECOMMENDATION: strong research recommendation: further data are needed on 
appropriate surveillance intervals in LGD. 
There is almost no data on different surveillance intervals or its effects in unselected 
populations of LGD.  (Conio et al., 2003)  The only study to date powered to evaluate the 
influence of surveillance on cancer mortality, among all patients with BE, found no 
substantial reduction in mortality for surveillance within three years.  (Corley et al., 2013)  
Recent data from large registries, which combined surveillance with radiofrequency 
ablation, have suggested lower-than-expected rates of progression to cancer; however, 
these studies lacked comparator populations of patients not in surveillance and did not 
assess mortality. (Haidry et al., 2013) ,  (Gupta et al., 2013) ,  (Phoa et al., 2014)   
 
Management strategies  
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19. Endoscopic ablation therapy should not be offered routinely to patients with non-
dysplastic BE.  Overall agreement 92.4%.  A+ 58.8%, A 33.6%, U 1.7%, D 0.8%, D+ 5%. 
RECOMMENDATION: we suggest against ablation therapy in benign BE.   
Conditional recommendation, low quality of evidence  
There are no large studies with long-term follow-up which provide evidence that 
endoscopic non-dysplastic BE ablation decreases the risk of malignant transformation along 
with an assessment of risks of harm and the need for further surveillance after ablation. (Li 
et al., 2008) Also, studies with follow up after ablation indicate that no ablation technique 
can achieve 100% BE ablation (Manner et al., 2006), (Manner et al., 2011), (Madisch et al., 
2005), (Shaheen et al., 2009), (Shaheen et al., 2011),  and neo-squamous epithelium after 
ablative treatment may still contain buried glands (Gray et al., 2011) that could be 
associated with progression to cancer. (Hage et al., 2006) Also, prophylactic BE ablation 
does not appear to be cost- effective. (Hur et al., 2012)   
20. Patients with BE with LGD on a single occasion (confirmed by at least 2 specialist GI 
pathologists), without higher risk features (including multi-focality, long segment.) 
should be managed with continued more frequent (6 to 12 months surveillance) 
(providing the patient is fit for endoscopy and not already undergoing therapy). 
Overall agreement 88%.  A+ 17.3%, A 70.7%, U 6.7%, D 4%, D 1.3%.   
Overall, the majority of patients diagnosed with LGD do not progress to HGD/EA. The overall 
rate of progression as reported by Wani et al.(Wani et al., 2011c) was 0.44% per year from 
LGD to EA and 1.83% per year to HGD or EA combined. LGD is subject to a high degree of 
interobserver variability and is challenging to diagnose in the setting of inflammation. LGD 
may be overcalled and often does not get confirmed on subsequent review by additional 
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expert gastrointestinal pathologists as demonstrated in a Dutch study (Duits et al., 2014) 
where 73% of cases that were initially diagnosed with LGD were downstaged to either non 
dysplastic BE or IND.  
A surveillance endoscopy in unifocal LGD does provide the opportunity to determine if 
there is progression, persistence, or regression. In cases of persistence (i.e. LGD present at a 
second, confirmatory endoscopy, (Abdalla et al., 2014) there is evidence to suggest these 
patients may be at higher risk and may consider the benefit of therapy to warrant the risk of 
therapy, as the SURF study (Phoa et al., 2014) demonstrated, persistence of LGD over time 
was predictive of progression in the control group. In cases of regression where LGD is no 
longer found on the subsequent endoscopy, continued surveillance is warranted to ensure 
that there is no further dysplasia. However, there is some uncertainty in these cases as to 
whether this due to is true regression, an issue of sampling error, inter-observer variability 
among pathologists, or removal of the dysplastic foci by the tissue sampling. These issues 
underscore the need for detailed endoscopic examination, (providing the patient is fit for 
endoscopy and not already undergoing therapy), re-review of dysplasia by at least 2 expert 
gastrointestinal pathologists and need for additional means of risk stratification. (Phoa et 
al., 2014) Risk stratification is needed to identify the subset of patients who are likely to 
progress and for whom the there is a likely benefit from ablation therapy and in whom the 
risks of the therapy are warranted. In an unselected group of patients with LGD, these risks 
may outweigh the benefits. Therefore, patients with BE with LGD confirmed by at least 2 
specialist GI pathologists should have a repeat endoscopy to confirm the findings, with 
recent guidelines recommending a broad 8 week to 12 month interval depending on the 
society (SFED, AGA, ASGE, BSG). If LGD confirmed by at least 2 specialist GI pathologists is 
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found on a single occasion only, (confirmed by repeat endoscopies) and without higher risk 
features (multi-focality, long segment, etc.) surveillance should be continued at 6 -12 
months intervals, to permit frequent sampling because they may fall into the persistent LGD 
group. An unselected group with LGD may gain little benefit from ablation therapy as the 
risks of therapy may outweigh the benefits. The options should be discussed with each 
patient to enable an acceptable decision. 
RECOMMENDATION: we suggest that patients with LGD on a single occasion 
(confirmed by at least 2 specialist GI pathologists), should be managed with continued 
more frequent (6 to 12 months surveillance) (providing the patient is fit for endoscopy and 
not already undergoing therapy). 
Patients who have confirmed absence of LGD after 2 consecutive endoscopic 
evaluations can revert to routine surveillance rather than intensive surveillance. 
Conditional recommendation, low quality evidence. 
 
21. Absence of dysplasia in 2 subsequent consecutive endoscopic evaluations, after an 
initial diagnosis of LGD in BE, identifies a cohort of patient who are at low risk to 
progress to dysplasia or EA and can continue routine surveillance rather than intensive 
surveillance. Overall agreement 90.7%.  A+ 21.3%, A 69.3%, U 6.7%, D 0%, D+ 2.7%.   
BE predisposes to the development of EA. Studies have reported a great variation in the 
progression rate to HGD or EA in the presence confirmed LGD between 0.84 to 9.1% per 
year (Duits et al., 2014), (Picardo et al., 2014, Wani et al., 2011b, Sikkema et al., 2011) One 
recent study (Thota et al., 2014) reported that patients with multi-focal LGD was associated 
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with an increased risk of developing HGD and EA, but Wani in 2011 (Wani et al., 2011b) 
reported no association for multi-focal LGD for either dysplastic progression or even 
persistence of LGD at repeat endoscopy. It is clear that if a patient is diagnosed with 
dysplasia (confirmed by at least 2 specialist GI pathologists) they should have a repeat 
endoscopy to confirm the findings, with recent guidelines recommending a broad 8 week to 
12 month interval depending on the society (SFED, AGA, ASGE, BSG). If the repeat 
endoscopy shows the regression of dysplasia a further endoscopy should be performed and 
if dysplasia is still absent the patients appear to be at lower risk of developing EA, 
comparable to patients that have not been diagnosed with LGD. These patients can 
continue routine rather than intensive surveillance as supported by studies (Conio et al., 
2003) including that by Duits (Duits et al., 2014) which showed reduced risk of developing 
EA in the absence of persistent LGD. 
22. Patients with BE with multi-focal LGD (confirmed by at least 2 GI pathologists) have an 
increased risk for progression of neoplasia compared with those with focal LGD. 
Overall agreement 86.7%.  A+ 30.7%, A 56%, U 13.3%, D 0%, D 0%.   
For discussion, see under statement 23. 
23. Patients with BE with LGD (confirmed by at least 2 GI pathologists) that persists, have 
an increased risk for progression of neoplasia compared to those with LGD at a single 
endoscopy. Overall agreement 89.3%.  A+ 36%, A 53.3%, U 9.3%, D 1.3%,  D+ 0%.   
 
The absolute risk of neoplastic progression (to HGD or EA) in BE patients with LGD has 
been controversial. Some studies have shown none or minimal increased in risk whereas 
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others have demonstrated significant increase in risk. Similarly, the patient phenotypic 
characteristics of LGD in BE (e.g., focal vs. multi-focal, short-segment vs. long-segment, 
persistent over time vs. intermittent, (i.e. found at a second confirmatory endoscopy, 
(Abdalla et al., 2014) at a surveillance interval of 6 to 12 months, consensus pathological 
agreement, etc.) have variably been described as important in predicting progression 
(Sikkema et al., 2011). Wani and colleagues followed more than 200 patients with Barrett ‘s 
and LGD for greater than 6 years (mean) and found none of these variables predicted 
histological progression. There are several studies which indicate that patients with 
persistent, multifocal LGD in a longer segment of BE are more likely to progress to EA 
(Shaheen et al., 2009), (Abdalla et al., 2014)and Thota et al. found a correlation between 
multifocality of LGD and progression of neoplasia (EA) in a single center experience of over 
1500 patient-years and a 6% decreased likelihood of dysplastic regression per 1 cm increase 
in BE length. Moreover, recently Phoa, et al, in a large RCT (Phoa et al., 2014), demonstrated 
that persistence of LGD over time and length of BE was predictive of progression in the 
control group. A rigorously stratified subset of patients with LGD with a consensus diagnosis 
of LGD by an expert panel may demonstrated a higher risk of progression of neoplasia as 
demonstrated in a recent retrospective histological and clinical study of LGD in the 
Netherlands. These patients with confirmed LGD had a significantly higher rate of 
progression to HGD/EA (9.1% per patient-year compared to 0.6% per patient-year among 
those initially diagnosed with LGD but then downgraded to non dysplastic BE and 0.9% for 
those downgraded to IND).  
24. Patients with BE with LGD (confirmed by at least 2 GI pathologists) and high-risk 
features (multifocality, segment length, persistence) should be offered treatment 
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options including ablative therapies. Overall agreement 89.3%.  A+ 36%, A 53.3%, U 
9.3%, D 1.3%, D+ 0%.   
For discussion, see below next statement, and discussion following statement 23. 
 
25. Ablative therapy (with scheduled follow up) it decreases the progression of neoplasia 
in BE with LGD (confirmed by at least 2 expert GI pathologist) and with risk factors 
(persistence, long BE segment, multifocality).Overall agreement 88%.  A+ 30.7%, A 
57.3%, U 9.3%, D 2.7%, D+ 0%.   
 
RECOMMENDATION: we suggest that patients with LGD (confirmed by at least 2 
specialist GI pathologists), and higher risk features (multifocality, segment length, 
persistence)  should be  offered treatment options including ablative therapies as ablative 
therapy decreases the progression to EA. 
Conditional recommendation, moderate quality evidence. 
 
Ablation of BE in patients with only LGD remains controversial because of the lack of 
reproducible data on cancer risk or clarity as to the clinical features that confer increase risk 
in BE patients with LGD. However, in high quality studies that have evaluated neoplasia 
progression in patients with BE LGD, ablation therapy has consistently improved outcomes 
by reducing neoplastic  progression (to EA). Indirect evidence would suggest considering a 
policy of diagnostic endoscopic resection (ER) in patients with LGD and endoscopically 
visible lesions in BE followed by ablation therapy. in BE followed by ablation therapy. There 
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is some evidence from RCTs and case studies that the durability of LGD eradication is long 
lasting. However, in these studies there is increased recognition of buried dysplasia 
presenting later as advanced cancer, thus justifying complete eradication of the BE with a 
wide area method (e.g. RFA) if focal eradication with ER was the initial therapy and BE 
remains. In the (SURF) RCT of surveillance versus radiofrequency ablation (Phoa et al., 2014) 
of participants with confirmed LGD, RFA significantly reduced neoplastic progression to 
HGD/EA, as compared to continued surveillance of BE with LGD (control arm). Histological 
progression decreased from 26.5% (control) to 1.5% (RFA). However during follow up, 10 % 
of patients had recurrent BE, suggesting continued surveillance is mandatory.  However 
after follow up, 10 % of patients had recurrent BE, suggesting continued surveillance is 
mandatory. The most common adverse event in the treatment group was stricture (7.4%). It 
should be noted that some have commented that these progression rates are higher than 
the reported rates of LGD progression in studies from other countries suggesting possible 
variability in the diagnosis or populations with BE and LGD. However, the original RCT of RFA 
(Shaheen et al., 2009) also demonstrated improvement in outcomes in those with LGD 
undergoing BE ablation which was durable (Shaheen et al., 2011)  Thus ablation of BE with 
LGD is supported by two high quality RCTs. While the best clinical marker(s) for predicting 
neoplastic progression in BE with LGD remains unclear, ablation of the lesion is associated 
with improved outcomes in reduced neoplastic progression in a subset of patients with LGD.  
These findings need to be tempered with other data suggesting a lower rate of 
progression of LGD (Hvid-Jensen et al., 2011, Bhat et al., 2011) (Wani et al., 2011a) which  
would suggest that overall, the majority of patients diagnosed with LGD do not progress to 
HGD/EA and may gain little benefit from ablation therapy.  However LGD on initial biopsy is 
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an indicator of the potential for disease progression and a registry with over 1000 patients 
reported that LGD present on the index endoscopy was associated with a rate of 
progression to HGD/EA of 6.5% per year, and 3.1% when tertiary referrals were excluded. 
(Picardo et al., 2014) Risk stratification (including expert GI pathologist consensus review)  is 
needed to identify the subset of patients with LGD for whom the there is a likely benefit 
from ablation therapy and in whom the risks of the therapy are warranted. In an unselected 
group of patients with LGD, these risks may outweigh the benefits. The options should be 
discussed with each patient to enable an acceptable decision.  
 
26. Management of IND in BE should require review and agreed consensus diagnosis by at 
least 2 gastrointestinal pathologists and follow up endoscopic biopsies within 12 
months after increased acid suppressive therapy. Overall agreement 92%.  A+33.5 %, A 
58.7%, U 6.7%, D 1.3%, D+ 0%.   
 
RECOMMENDATION: we suggest that patients with the diagnosis of IND (confirmed by 
at least 2 specialist GI pathologists), should be re-biopsied within 1 year to detect 
prevalent neoplasia and should have their acid suppression (usually with a PPI) 
increased. 
Conditional recommendation, very low quality evidence  
Note: the diagnosis of IND  should be considered as an interim diagnosis only. Further 
endoscopic surveillance (after acid suppressive therapy and within one year or sooner) 
is required to up- or down- grade the dysplasia after careful biopsy sampling/*ER. 
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*We have used ER throughout as the standard term as is interchangeable with endoscopic 
mucosal resection (EMR) but more accurately descriptive of the technique. 
Follow up is recommended because of uncertainty about the nature of the lesions 
classified as IND. (Schlemper et al., 2000) Some follow up studies have shown increased 
likelihood of progression to higher grades of neoplasia, (Montgomery et al., 2001), 
(Sonwalkar et al., 2010) but this seems to be only in the first year, representing prevalent 
cases (Horvath et al., 2014). The risk appears higher in patients with multifocal IND (Younes 
et al., 2011) but is similar to a population with non-dysplastic BE when the diagnosis of ‘IND’ 
(rather than LGD) has been confirmed by a consensus panel of 2 (Curvers et al., 2010) or 6 
expert GI pathologists. (Duits et al., 2014) 
It has been suggested (without supporting evidence) that patients with ‘regenerative’ 
changes and inflammatory infiltration require increased acid suppression with proton pump 
inhibitor (PPI) therapy before re-biopsy. (Fitzgerald et al., 2014) (Montgomery et al., 2001) It 
is not clear what the interval for re-endoscopy and biopsy should be: the BSG guidelines 
suggest 6 months (by consensus rather than evidence). However, the finding that increased 
incidence of cancer occurs in the first year  (Horvath et al., 2014) suggests that a 6-12 month 
interval is reasonable. These data suggest that all cases of ‘IND’ should be re-biopsied within 
1 year to detect prevalent neoplasia. Although evidence is lacking, those with inflammatory 
infiltration and regenerative changes should have their acid suppression (usually with a PPI) 
increased.  
27. Routine ER should not be offered routinely to patients with non-dysplastic BE.  Overall 
agreement 96.7%.  A+ 59.2, A 37.5%, U 2.5%, D 0%, D+ 0.8%.   
For discussion see 29. 
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RECOMMENDATION: we suggest against ER in patients with non-dysplastic BE and 
no visible lesion (harms outweigh benefits)   
Conditional recommendation, low quality evidence 
28. BE patients with visible lesions in the BE segment should have ER to stage the lesion.  
Overall agreement 87.6%.  A+ 46.3%, A 41.3%, U 9.1%, D 3.3%, D+ 0%.   
For discussion see 29. 
29. ER of visible endoscopic lesions in diagnosed LGD should be carried out to enable 
accurate histological assessment. Overall agreement 94.7%.  A+ 74.4%, A 20%, U 5.3%, 
D 0%, D+ 0%.   
RECOMMENDATION: we suggest patients with a visible lesion in  non-dysplastic BE (as 
well visible lesions in BE with LGD or IND), should have ER (followed by ablation if HGD 
or intramucosal cancer is detected) over simple biopsies. 
Strong recommendation, low quality evidence for non-dysplastic BE; moderate quality 
evidence for LGD. 
ER of visible lesions (nodules and irregularities visualized by conventional endoscopy), 
without obvious signs of invasion) in previously confirmed LGD with the diagnosis confirmed 
by at least 2 expert GI pathologists should be carried out to enable accurate histological 
assessment. ER may result in a change of diagnosis of LGD. Wani (Wani et al., 2013) 
reported a series of one-hundred and thirty-eight BE patients LGD 15 (10.9 %), HGD 87 (63 
%), EA 36 (26.1 %)) were included; 114 (82.6 %) patients had visible lesions. ER resulted in a 
change of diagnosis for 43 (31.1 %) patients (upgrade 14 (10.1 %); downgrade 29 (21 %)). 
The report of that study states that "For patients diagnosed with LGD on biopsies (n = 15), 
ER resulted in downstaging for two (13.3 %) cases and upstaging for five (33.3 %) cases. 
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Visible lesions were noted for eight (53.3 %) of cases." The most common adverse effects 
due to ER are bleeding, scarring (leading to stricture) and risk of perforation. (Pech et al., 
2006)   
In case of suspicious areas or raised lesions within the BE segment, ER is able to not only to 
provide a true tissue diagnosis including the character and extent of a potential abnormality 
(Spechler et al., 2011a), but also to be a treatment approach with a curative intent if early 
cancer is detected. (Ell et al., 2000) In contrast to ER, ablative treatment approaches alone, 
such as RFA, destroy the tissue without being able to gain a pathology specimen, and should 
therefore not be used in case of suspicious or raised lesions within the BE segment. 
In the event that visible lesions in LGD assessed with ER detects HGD or T1a cancer, this 
should be treated by an appropriate ablation or treatment method if is detected. (Bennett 
et al., 2012b), (Bennett et al., 2012a) 
 
There are no studies that have specifically looked at benign BE in which nodules or 
depressed areas have been detected, but if examination reveals these types of 
abnormalities, indirect evidence, since it is related to patients with dysplasia, suggests that 
ER should be used as neoplasia may be present. (Pech et al., 2014), (Haidry et al., 2013), 
(Wani et al., 2013)  Macroscopic surface abnormalities should be graded using the Paris 
modification of the Japanese system for classification of early gastric neoplasia.  (Endoscopic 
Classification Review, 2005) 
A biopsy finding of LGD in BE, especially if multifocal, carries a higher risk of 
progression to HGD or cancer than benign BE. (Montgomery et al., 2001), (Srivastava et al., 
2007), (Younes et al., 2011) ER may result in a change of diagnosis of LGD. Flat type 2b 
lesions are the commonest seen among patients with dysplasia referred for high resolution 
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endoscopy at expert centers (Pech et al., 2007).  Two studies have shown that the risk of 
malignancy unsuspected on initial biopsy is greatest with polypoid (type 1) or depressed 
(type 2c or 3) lesions. (Pech et al., 2007), (Peters et al., 2008a)  
RECOMMENDATION: we recommend that ER should be followed by ablation if HGD 
or intramucosal cancer is detected, rather than continued surveillance. 
Conditional recommendation, low quality evidence 
 
 
Molecular markers of dysplasia and progression 
 
30. Aberrant p16, p16 methylation or p16 loss in non-dysplastic BE is associated with an 
increased risk of progression to LGD.  Overall agreement 80%. A+13.3%, A66.7%, 
U19.2%, D 0.8%, D 0%.  
There is evidence that p16 hypermethylation is an early predictor of progression in 
BE, especially for LGD.  "Patients who progressed from baseline pathology to HGD or cancer 
had higher prevalence of hypermethylation in their initial esophagus biopsies compared 
with those who did not progress for p16 (100 vs.  33%; P=0.008)".  (Wang et al., 2009)  p16 
is not the only marker studied for aberrant methylation and others include HPP1, RUNX3, 
AKAP12, CDH13, SST, TAC1, NELL1,  (Jin et al., 2009) and which have also been replicated in 
another study.   (Sato et al., 2008) 
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31. Aberrant p53, p53 mutation or p53 loss in non-dysplastic BE is associated with an 
increased risk to develop dysplasia.  Overall agreement 87.7% A+ 26.2%, A 61.5%, U 
10.7%, D 0.8%, D+0.8%.   
There is extensive evidence that p53 overexpression is a predictor of progression in 
BE, especially for LGD  (Bian et al., 2001), (Campomcnosi et al., 1996), (Carlson et al., 2002), (Cawley et al., 1998), (Doak et al., 
2003), (Flejou et al., 1999), (Shi et al., 1999), (Sikkema et al., 2009b, Sikkema et al., 2009a) and that p53 overexpression is 
caused by mutations that lead to a hyperstable p53 protein overexpression (that greatly 
lengthen its half-life).  When this overexpression is detected by immunohistochemistry, it is 
an excellent predictor of progression in all BE. (Kastelein et al., 2013)   
We further examined whether p53 abnormal staining is useful as an adjunct to the 
histopathological assessment of dysplasia and its utility as a progression marker.  The 
following two statements (32 and 33) did not reach consensus and the reasons cited were 
lack of clarity in the association between dysplasia, progression and p53 immunoreactivity 
and readiness for clinical application.  We therefore recommend that further research 
should be done to determine the role of these biomarkers and their clinical utility. 
32. p53 aberrant expression combined with histopathological assessment of LGD is more 
accurate than histopathological assessment alone in specialist centers. Overall 
agreement 40%. A+ 12%, A 28%, U 38.7%, D 17.7%, D+ 2.7%. 
33. p53 aberrant expression combined with histopathological assessment is not useful for 
the histopathological assessment of dysplastic progression in non-dysplastic BE. 
Overall agreement 38.7%. A+ 12%, A 26.7%, U 44%, D 13.3%, D+ 1.3%. 
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RECOMMENDATION: strong research recommendation.  Test the utility of these 
markers as adjuncts in the histological assessment of  dysplasia, and as methods of risk 
stratification. 
Prevention of progression 
Chemoprevention with aspirin, statins or diet was not agreed in this consensus (see 
online appendix, Results).   
34. The use of PPI's (compared to no therapy or histamine receptor type 2 antagonists 
(H2RA)s is associated with a decrease in progression from benign BE metaplasia to BE 
neoplasia (dysplasia and EA).  Overall agreement 53.3%.  A+ 10.8%, A 42.5%, U 20.8%, 
D 23.3%, D+2.5%.   
RECOMMENDATION: Strong research recommendation for more data from the  
aspirin esomeprazole chemoprevention trial (AspECT ) trial. 
There is no evidence from high quality prospective trials (RCTs) that PPI use prevents 
progression of BE to neoplasia but there is scientific plausibility (prevention of injury leading 
to mutational events and neoplasia).  (Umansky et al., 2001)  Cohort studies demonstrate 
the use of PPIs decreased neoplasia development. (El-Serag et al., 2004) , (Hillman et al., 2004) , (Hillman et al., 
2008) , (Nguyen et al., 2009) A systematic review (Islami et al., 2009) reported a strong inverse 
association between PPI use and the risk of EA or HGD in patients with BE.   
Surgical therapies for prevention of progression. 
Anti-reflux surgery offers an alternative to PPIs in the treatment of GERD: it corrects 
lower esophageal sphincter failure, associated HH, and controls abnormal gastric and 
duodenal reflux in 80-90% of patients.   
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35. Rates of progression to dysplasia or cancer in patients with BE are similar when 
comparing medical management to fundoplication.  Overall agreement 86.6%.  A+ 
28.6%, A 58%, U 10.1%, D 2.5%, D+ 0.8%.   
Some cohort studies suggest that effective anti-reflux surgery may reduce the risk of 
progression.  (Gurski et al., 2003) , (Zehetner et al., 2010) , (Zaninotto et al., 2012) However, 
in a study of 101 patients, there was no difference in the development of HGD comparing 
acid suppression (5%) and fundoplication (3%) after a median follow-up of 5 and 6 years, 
respectively. (Parrilla et al., 2003)  A meta-analysis (Corey et al., 2003) comparing anti-reflux 
surgery to PPI in patients with BE demonstrated a similar incidence of progression to 
dysplasia or cancer. However, a systematic review of 25 reports that included long-term 
follow-up of medically and surgically treated BE patients found that overall, there was an 
increased incidence of EA in medically-treated patients. (Chang et al., 2007)   
No difference in the incidence of EA was seen in one follow up study of an RCT and 
this study concluded that surgery alone will not prevent EA or remove the need for anti-
secretory medication. (Spechler et al., 2001) (Lodrup et al., 2014) Recently it has been 
shown that progression to cancer after anti-reflux surgery is mainly related to late 
recurrence of reflux.  (Lagergren et al., 2010) , (Lofdahl et al., 2011) , (Lofdahl et al., 2013)   
RECOMMENDATION: we suggest against anti-reflux surgery beyond establishing 
reflux control in patients with BE and we suggest using medical therapies over surgical 
therapies for preventing progression to dysplasia or cancer in patients with BE. 
Conditional recommendations, moderate quality of evidence 
Note: patients placing a lower value on potential complications from surgery and a 
higher value on avoiding daily medications may opt for surgical approaches. Patients 
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should be counselled that acid suppression medications may need to be used on a long 
term basis after surgery. 
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DISCUSSION  
In our post hoc voting rounds, we agreed a universal definition of BE i.e. “BE is defined 
by the presence of specialized columnar mucosa in the esophagus and it should be stated 
whether intestinal metaplasia (IM) is present above the gastroesophageal junction.” This 
definition may help future research and audit by amalgamating both the divergent 
European (non-IM allowed) and the U.S. (IM only allowed) systems. (Rugge et al., 2014) The 
true malignant potential of BE with or without IM is presently unknown and our new 
definition and requires that the pathology report should state whether IM is present or 
absent in the tissue samples taken from above the gastro-esophageal junction (GOJ), which 
is a departure from the U.S requirement for IM to be present. (McNally, 2015) In addition 
because the GOJ is mentioned explicitly for the first time it emphasizes how important it is 
to distinguish  BE from the commonly associated HH below. However in order to make the 
definition more robust for the clinic, further refinements may require IM to be present up to 
a certain length to help differentiate BE from columnar tissue taken from HH.  
We recommend that consensus be required from  least two specialist GI pathologists for 
the diagnosis of dysplasia (of any grade, including ‘IND’) which is in accordance with the new 
BSG guidelines. (Fitzgerald et al., 2014) This may have short term resource implications for 
extra histopathology staff but longer term the increased accuracy will lead to better long 
term management and greater efficiency.  There is no evidence pointing to an optimal 
number of pathologists required, but evidence indicates accuracy increases with up to 3 
experts involved. (Sanders et al., 2012), (Duits et al., 2014), (Coco et al., 2010),(Montgomery 
et al., 2001) , (Sonwalkar et al., 2010) 
47 
 
The format and content of the proposed pathology proforma for BE requires further 
clarification.  We recommend the proforma such as the example proposed in the BSG 
guidelines in 2014 (Fitzgerald et al., 2014) as good practice but if adopted, the individual 
features would have to be chosen by GI pathology experts. 
 
There is currently no case for population screening for BE to reduce the risk of death 
from EA.  We were unable to agree a policy of endoscopic screening except in very high risk 
groups such as  males over 60 with poorly controlled GERD >10 years.  EA is relatively rare in 
women, and demographic groups who are less at risk of EA,  therefore endoscopic 
investigation would usually be employed in these groups only in the context of 
investigations of dyspepsia, to  permit diagnosis and treatment of other conditions causing 
GERD symptoms (e.g., gastritis). 
Although it is uncommon for BE patients to develop EA, (Bhat et al., 2011, Hvid-
Jensen et al., 2011) in recent population based studies looking at outcomes from 
surveillance taking into account lead time bias and length bias, surveillance of BE leads to 
diagnosis of EA at an earlier stage, and  improved survival from EA(Bhat et al., 2014) and is 
cost-effective if undertaken every 5 years for non-dysplastic BE and every 3 years for LGD, in 
long-segment BE. (Kastelein et al., 2014) We did not perform cost effectiveness analyses of 
regular surveillance in these scenarios, but cost-effectiveness is unlikely if the prevalence 
rates of cancer in BE is less than 0.5 per year.   
We now have very strong agreement on stratification of risk for targeted surveillance 
in high risk groups , including, but not limited to: age and sex, length of segment, and 
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symptom duration, frequency and severity. Whether or not non-dysplastic BE patients are 
followed up with routine surveillance to decrease their risks of death from EA, should not be 
determined solely on the basis of presence or absence of IM. There was agreement that 
longer length BE has a greater risk of progression to EA amongst other factors, (Sikkema et 
al., 2011) including obesity and tobacco smoking. Appreciation of risk factors in BE could 
potentially be developed into a  quantitative score comparable to the acute physiology and 
chronic health evaluation (APACHE) risk classification of severely ill adult patients,  to help 
physicians to determine each patient’s need, and the most appropriate interval to return for 
endoscopic surveillance. The risks and benefits of surveillance should be taken into account 
with the patient’s input particularly in those patients with co-morbidities or short life 
expectancy. 
Future research including evaluation of genetic markers to determine cancer risk 
(Nicholson and Jankowski, 2009) , (Cronin et al., 2011) and biomarkers of progression 
(Rubenstein et al., 2005),(Rubenstein, 2014) may also permit selection of higher risk groups 
for endoscopic surveillance, or treatment.  We make no recommendation to proceed with 
routine use of biomarkers in practice but given the high levels of agreement, the adoption of 
these markers in specialist centers could be considered.  The problem is that while in the 
main voting round people were very compelled by the association of for example p53 with 
dysplasia and cancer progression, in the post hoc voting rounds when we tried to dissect out 
the specific clinical utility of p53, the agreement fell apart because of weak specific 
evidence.  
 
49 
 
If undertaken, endoscopic surveillance of a patient with BE should be carried out in a 
careful and systematic manner to assess extent, histological features and risk factors, to 
guide subsequent management.  Currently most BE surveillance endoscopies do not adhere 
to the empirical principles of good endoscopic practices; adequately trained staff, dedicated 
lists, and adequate biopsies taken.  In the latter issue there is still disagreement as to 
whether Seattle is the only adequate method. We narrowly missed reaching consensus on 
the optimum number of biopsies to be taken during surveillance endoscopies in non-
dysplastic BE being 2 per cm of BE length (76% overall agreement) and we make a strong 
research recommendation that further research is needed to identify the number of 
biopsies to detect progression for use as a quantitative metric. 
Dedicated lists can allow adequate time to examine BE segments, to use adjunctive 
techniques which may improve neoplasia detection in a surveillance setting(Tholoor et al., 
2014) and to carry out systematic protocolized biopsies as well as targeted biopsies of 
visible abnormalities. However, while a single center study (Anagnostopoulos et al., 2006) 
reported that establishing a specialist BE clinic reduced variation in treatment, changed 
management and improved adherence to local guidelines, there is no clear evidence yet 
that that specialized referral units for BE, centralized BE surveillance services dedicated 
surveillance lists can be confidently recommended. Statements on surveillance intervals in 
non-dysplastic BE and unselected populations of LGD were not agreed, probably reflecting 
lack of confidence in the data rather than the empirical recommendations of any  guidelines 
(Garside et al., 2006), (Barritt and Shaheen, 2008) cited.   
We now have consensus on a new bi-directional pathway to de-escalate or escalate 
the risk of patients with low risk BE compared with those with potentially higher risk BE such 
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as IND, or LGD with persistence over 2 endoscopies, multifocality, and long-segment BE. 
Patients with persistent and confirmed LGD should be treated by ablative therapy, which 
decreases progression to neoplasia (Phoa et al., 2014), and not just followed up.  If not 
treated, in the case of LGD found on a single occasion, follow up should be close and biopsy 
protocols strict, as many may also have, or go on to develop HGD.  The diagnosis of IND 
should be considered a holding diagnosis only and prompt further close follow up with 
adequate biopsy sampling. 
Routine ER or routine endoscopic ablation therapy was not accepted as a strategy 
for non-dysplastic BE as the risk of harms outweighs any benefits. In the event of visible 
lesions in non-dysplastic BE and in all cases of dysplasia (LDG, IND)  we recommend ER 
followed by an appropriate ablation method, as this  offers a route of intervention to 
diagnose and treat early neoplasia.  The SURF trial (Phoa et al., 2014)  found that RFA was 
associated with a reduction in disease progression in patients with LGD confirmed by an 
expert panel of pathologists.  It is unclear if these results can be generalized to routine 
management of patients with LGD. (Almond et al., 2014) There is some evidence that 
radiofrequency ablation (RFA), with or without endoscopic resection of BE containing 
confirmed LGD is long lasting. 4(Phoa et al., 2014)   However there is the increased 
recognition of buried dysplasia presenting later as advanced cancer, but in most cases this 
recurrence occurs in small islands or tongues; this would suggest a policy of continued 
endoscopic surveillance post-eradication with careful sampling to detect recurrence or 
progression of disease, but there is no evidence to recommend what surveillance intervals 
should be employed.   
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There was strong agreement that rates of progression to dysplasia or cancer in 
patients with BE are similar when comparing medical management to fundoplication.  The 
studies are underpowered for patients with BE; however, there are no obvious reasons to 
conclude that the comparative efficacies of medical and surgical therapy differ for symptom 
control between BE patients and GERD patients. (Attwood et al., 2008) There are adverse 
events and considerable costs associated with surgical therapies compared with PPI therapy 
and patients may need to continue with PPI medication after surgery. (Lodrup et al., 
2014)  Fundoplication should not be offered to GERD patients, with or without BE, with the 
intent of reducing the risk of progression to BE or EA. 
Our multidisciplinary international group has developed consensus to help the 
practicing clinician with the diagnosis and management of BE.  There are a number of other 
potential limitations of this study; namely that we did not use meta-analysis techniques in a 
more rigorous approach to evaluating the literature, although we drew on evidence from 
existing meta-analyses, and some geographical areas (Africa, South America, Far Eastern 
and Middle Eastern countries, Russia), were underrepresented, despite our efforts for wide 
recruitment.  There was some uncertainty in the voting process.  In the intermediate voting 
round, Round 2, many participants registered a null vote and we saw a lack of a consistent 
downward progression in null (neither agree nor disagree votes) for some statements which 
may have been due to development and referencing of the statements reflecting the 
difficulty in obtaining scientifically valid studies about this condition. Other voters used the 
‘neither agree nor disagree’ option to indicate true equipoise.  Commenting and rigorous 
editing and refinement reduced the uncertainty by the final round.  The relatively poor 
quality of data relating to BE is emphasized by 8 statements included in this summary having 
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low or very low levels and 3 having moderate levels of evidence quality.  However, it is 
unlikely that large, well-designed randomized trials will ever be done, although the 
comparison of therapeutic interventions such as aspirin and different PPI doses will be 
reported in the AspECT trial (a phase III, randomized study of aspirin and esomeprazole 
chemoprevention in BE metaplasia) and BOSS (Barrett’s Oesophagus Surveillance Study) 
addresses scheduled endoscopic surveillance versus ‘at need’ endoscopic surveillance.   
In conclusion, the process we employed and the large number of reviewers probably 
reflects expert opinion better than in any traditional guideline or consensus processes and 
represents the most far-reaching, inclusive, and informative consensus process on 
evaluation and management of BE and LGD published to date.  We made strong research 
recommendations to prioritize future research and in particular we provide for the first time 
an agreed global definition of BE together with a pathway of escalation and de-escalation of 
indefinite dysplasia or LGD.  
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